ENTYVIO is the only biologic developed and approved just for UC and Crohn’s. ENTYVIO works at the site of inflammation in the gastrointestinal (GI) tract, and is clinically proven to help many patients achieve both symptom relief and remission. If you’re ready for a change, ask your doctor about achieving symptom relief and remission with ENTYVIO. Individual results may vary.

You can use our helpful doctor discussion guide to start a conversation about your treatment with your doctor.

Download it at ENTYVIO.com/Doctor-Discussion-Guide

If you haven’t experienced the results you’re looking for from other treatments, including steroids, immunosuppressants, or biologic therapies, ask your doctor about ENTYVIO.*

Many Patients with UC Achieved Relief and Remission

ENTYVIO treats GI inflammation that occurs in adults with moderately to severely active UC.

- In as early as 6 weeks, 47% of patients with UC achieved response*
- At 1 year, 42% of patients with UC achieved remission†.
  At 1 year, patients with UC were 2x more likely to achieve steroid-free remission versus those who took a placebo

*Compared to 26% of patients in response on placebo at 6 weeks
†Compared to 16% of patients in remission on placebo at 1 year

Individual results may vary.

Improvement Beyond Remission

In addition to early response and long-term remission at one year, some patients experienced improvement in how their intestinal lining looked to their doctor, indicating that their disease was less active.

- In as early as 6 weeks, 41% of patients with UC experienced improvement in how their intestinal lining looked to their doctor*
- At 1 year, 52% of patients with UC experienced improvement in how their intestinal lining looked to their doctor†

*Compared to 25% of patients on placebo at 6 weeks
†Compared to 20% of patients on placebo at 1 year

Learn more about a different kind of treatment for UC at www.ENTYVIO.com/UC.

Many Patients with CD Achieved Remission with ENTYVIO

ENTYVIO treats GI inflammation that occurs in adults with moderately to severely active CD. It works by focusing at the site of inflammation in the GI tract.

- In as early as 6 weeks, 15% of patients with CD achieved remission*
- At one year, 39% of patients with CD achieved remission†

*Compared to 7% of patients in remission on placebo at 6 weeks
†Compared to 22% of patients in remission on placebo at 1 year

Individual results may vary.

ENTYVIO (VEDOLIZUMAB) Provided Remission Without Depending on Steroids:

2X as many patients with CD taking ENTYVIO achieved steroid-free remission compared to patients on placebo at 1 year.

Learn more about a different kind of treatment for Crohn’s at www.ENTYVIO.com/CD

Uses of Envyvio® (vedolizumab):

ENTYVIO is a prescription medicine used in adults:

- with moderate to severe ulcerative colitis (UC) when certain other UC medicines have not worked well enough or cannot be tolerated.
  ENTYVIO may help to: begin reducing some symptoms, induce and maintain remission, reduce or stop the use of corticosteroids, and improve the way the lining of your large intestine looks to your healthcare provider.

- with moderate to severe Crohn’s disease (CD) when certain other CD medicines have not worked well enough or cannot be tolerated.
  ENTYVIO may help to: begin reducing some symptoms, achieve remission, and reduce or stop the use of corticosteroids.

Safety Considerations

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 3.
SAFETY CONSIDERATIONS
Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

Please see Important Safety Information on page 3.
IMPORTANT SAFETY INFORMATION ABOUT ENTYVIO® (VEDOLIZUMAB)

• Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients.

• ENTYVIO may cause serious side effects, including:
  • Infusion and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feel like your heart is racing).
  • ENTYVIO may increase your risk of getting a serious infection. Before receiving and during treatment with ENTYVIO, tell your healthcare provider if you think you have an infection or symptoms of an infection, such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, red or painful skin or sores on your body, tiredness, or pain during urination.
  • It may be possible for a person to get progressive multifocal leukoencephalopathy (PML) (a rare, serious brain infection caused by a virus). People with weakened immune systems can get PML, which can result in death or severe disability. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any of the following symptoms: confusion or problems thinking, loss of balance, change in the way you walk or talk, decreased strength or weakness on one side of the body, blurred vision, or loss of vision.
  • Liver problems can happen in people who receive ENTYVIO. Tell your healthcare provider right away if you have any of the following symptoms: tiredness, loss of appetite, pain on the right side of your abdomen, dark urine, or yellowing of the skin and eyes (jaundice).

IMPORTANT SAFETY INFORMATION (CONTINUED)

• The most common side effects of ENTYVIO include common cold, headache, joint pain, nausea, fever, infections of the nose and throat, tiredness, cough, bronchitis, flu, back pain, rash, itching, sinus infection, throat pain, and pain in extremities. These are not all the possible side effects of ENTYVIO. Call your healthcare provider for medical advice about side effects.

• Before receiving ENTYVIO, tell your healthcare provider about all of your medical conditions, including if you: have or think you may have an infection or have infections that keep coming back; have liver problems; have tuberculosis (TB) or have been in close contact with someone with TB; have recently received or are scheduled to receive a vaccine; or if you are pregnant, breastfeeding, plan to become pregnant, or plan to breastfeed.

Click here for Full Prescribing Information, including the Medication Guide, for ENTYVIO and talk with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

USES OF ENTYVIO® (VEDOLIZUMAB):

ENTYVIO is a prescription medicine used in adults:

• with moderate to severe ulcerative colitis (UC) when certain other UC medicines have not worked well enough or cannot be tolerated. ENTYVIO may help to: begin reducing some symptoms, induce and maintain remission, reduce or stop the use of corticosteroids, and improve the way the lining of your large intestine looks to your healthcare provider.

• with moderate to severe Crohn’s disease (CD) when certain other CD medicines have not worked well enough or cannot be tolerated. ENTYVIO may help to: begin reducing some symptoms, achieve remission, and reduce or stop the use of corticosteroids.
**EntyvioConnect: SUPPORT WHEN YOU NEED IT.**

Created to support you through every step of your ENTYVIO journey, **EntyvioConnect** offers resources and useful tips to help you manage your condition. When you enroll in **EntyvioConnect**, you will be able to access savings and financial assistance as well as receive support from your own dedicated registered nurse. So whether you have questions or just need someone to talk to, **EntyvioConnect** is here for you.

**EntyvioConnect FINANCIAL SUPPORT:**

**EntyvioConnect** Financial Support offers help no matter what your financial situation may be.

**Commercial insurance (PPO or HMO)**
If you have commercial insurance, you can take advantage of our co-pay program to pay as little as $5 per dose.*

**Government insurance (Medicare, Medicaid, TriCARE, etc.)**
If you have government insurance, you may be eligible to receive financial assistance from an independent co-pay foundation.

**No insurance**
If you have no insurance or are underinsured, you may be able to receive assistance from the Takeda Patient Assistance Program.

*For commercially insured patients who qualify, as part of EntyvioConnect Financial Support. Eligibility Requirements: This offer cannot be used if you are a beneficiary of, or any part of your prescription is covered by: (1) any federal or state healthcare program (Medicare, Medicaid, TriCARE, etc.), including a state pharmaceutical assistance program, (2) the Medicare Prescription Drug Program (Part D), or if you are currently in the coverage gap, or (3) insurance that is paying the entire cost of the prescription.

**YOUR NURSE CARE PARTNER IS READY TO HELP.**

**EntyvioConnect** Nurse Support:
Your Nurse Care Partner is a dedicated registered nurse, who has been specifically trained on ENTYVIO. The one-on-one support from your Nurse Care Partner can help with:

- Developing a personalized care plan
- Having an effective conversation with your doctor
- Answering questions about your treatment

*Our nurses do not provide medical advice*

**For more information about EntyvioConnect:**
1-844-ENTYVIO (1-844-368-9846) Monday to Friday, from 8am to 8pm ET (except holidays).
Visit us at www.ENTYVIO.com/support to enroll.

**RELIEF AND REMISSION WITHIN REACH**

If your moderate to severe ulcerative colitis or Crohn's disease symptoms are holding you back and your current treatment hasn't worked well enough, it may be time for a change. Ask your doctor about ENTYVIO, the only biologic developed and approved just for UC and Crohn's.

- ENTYVIO works at the site of inflammation in the GI tract, and can help many patients achieve both symptom relief and remission.
- To learn more about ENTYVIO call 1-844-ENTYVIO or go to www.ENTYVIO.com/signup and follow us on social media.

*Individual results may vary.*

**SAFETY CONSIDERATIONS**

Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients. Infusion and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. ENTYVIO may increase your risk of getting a serious infection.

*Please see Important Safety Information on page 3.*

**FOR MORE INFORMATION, PLEASE VISIT ENTYVIO.COM.**

ENTYVIO is a trademark of Millennium Pharmaceuticals, Inc., registered with the U.S. Patent and Trademark Office, and is used under license by Takeda Pharmaceuticals America, Inc. All other trademarks are the property of their respective owners.